Abstract
Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.
Original language | English (US) |
---|---|
Pages (from-to) | 294-314 |
Number of pages | 21 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 6 |
Issue number | 3 |
State | Published - Apr 11 2008 |
Fingerprint
Keywords
- Carcinoma
- Chemotherapy
- NCCN Clinical Practice Guidelines
- Pulmonary carcinogenesis
- Radiotherapy
- Small cell
- Surgical resection
ASJC Scopus subject areas
- Oncology
Cite this
Small cell lung cancer. / Kalemkerian, Gregory P.; Akerley, Wallace; Downey, Robert J.; Ettinger, David S.; Fossella, Frank; Grecula, John C.; Jahan, Thierry; Johnson, Bruce E.; Kessinger, Anne; Koczywas, Marianna; Langer, Corey J.; Martins, Renato; Niell, Harvey B.; Pan, Charles C.; Ramnath, Nithya; Ready, Neal; Robert, Francisco; Williams, Charles C.
In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. 3, 11.04.2008, p. 294-314.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Small cell lung cancer
AU - Kalemkerian, Gregory P.
AU - Akerley, Wallace
AU - Downey, Robert J.
AU - Ettinger, David S.
AU - Fossella, Frank
AU - Grecula, John C.
AU - Jahan, Thierry
AU - Johnson, Bruce E.
AU - Kessinger, Anne
AU - Koczywas, Marianna
AU - Langer, Corey J.
AU - Martins, Renato
AU - Niell, Harvey B.
AU - Pan, Charles C.
AU - Ramnath, Nithya
AU - Ready, Neal
AU - Robert, Francisco
AU - Williams, Charles C.
PY - 2008/4/11
Y1 - 2008/4/11
N2 - Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.
AB - Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.
KW - Carcinoma
KW - Chemotherapy
KW - NCCN Clinical Practice Guidelines
KW - Pulmonary carcinogenesis
KW - Radiotherapy
KW - Small cell
KW - Surgical resection
UR - http://www.scopus.com/inward/record.url?scp=41749085062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41749085062&partnerID=8YFLogxK
M3 - Review article
C2 - 18377848
AN - SCOPUS:41749085062
VL - 6
SP - 294
EP - 314
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
SN - 1540-1405
IS - 3
ER -